Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11517-11519

  Iga, Arthur M ^a   Sarkar, Sandip ^a,b   Sales, Kevin M ^a   Winslet, Marc C ^a,b   Seifalian, Alexander M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CM 101; COMBRETASTATIN A4; CYTOKINE; ENDOSTATIN; FLAVONOID; FOSTRIECIN; HISTAMINE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SEROTONIN; VASCULAR TARGETING AGENT;

BLOOD FLOW VELOCITY; BLOOD VESSEL DIAMETER; BLOOD VESSEL REACTIVITY; CELL ACTIVITY; CELL LABELING; CONTRAST ENHANCEMENT; DRUG ACTIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG TARGETING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; IMAGE QUALITY; IN VIVO STUDY; INTRAVITAL VIDEO MICROSCOPY; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VIDEORECORDING;

ANGIOGENESIS INHIBITORS; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSCOPY, VIDEO; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33846218999     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1743     Document Type: Review

References (20)

1. Sato TN. A new approach to fighting cancer? Proc Natl Acad Sci U S A 1998;95:5843-4.
2. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
3. Yakes FM, Wamil BD, Sun F, Yan HP, Carter CE, Hellerqvist CG. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. Cancer Res 2000;60:5740-6.
4. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine, and tumour necrosis factor α on colon 38 tumours in mice. Eur J Cancer Clin Oncol 1989;25:263-9.
5. Tozer GM, Bicknell R. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 2004;14:222-32.
6. Tozer GM. Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003;76 Spec No 1:S23-35.
7. Boehm T, Folkman J, Browder T, O'reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
8. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62:846-53.
9. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
10. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
11. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
12. Segreti JA, Polakowski JS, Koch KA, et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004;54:273-81.
13. Ohno T, Kawano K, Sasaki A, et al. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int J Clin Oncol 2002;7:171-6.
14. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-44.
15. Varghese HJ, Mackenzie LT, Groom AC, Ellis CG, Chambers AF, MacDonald IC. Mapping of the functional microcirculation in vital organs using contrast-enhanced in vivo video microscopy. Am J Physiol Heart Circ Physiol 2005;288:H185-93.
16. Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 2005;17:277-90.
17. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
18. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38.
19. Read TA, Farhadi M, Bjerkvig R, et al. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 2001;61:6830-7.
20. Ruh J, Ryschich E, Secchi A, et al. Measurement of blood flow in the main arteriole of the villi in rat small intestine with FITC-labeled erythrocytes. Microvasc Res 1998;56:62-9.